Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Molecular formula

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44256   clinical trials with a EudraCT protocol, of which   7344   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    172 result(s) found for: Molecular formula. Displaying page 1 of 9.
    1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2005-002989-11 Sponsor Protocol Number: 2005-10-01 Start Date*: 2006-02-02
    Sponsor Name:IIT : University Hospital - Medical Clinic II (Director: Prof. Dr. med. J. Floege - Sponsor)
    Full Title: Treatment of chronic glomerulonephritis with low molecular weight heparin (ClexaneR)
    Medical condition: Chronic glomerulonephritis, a chronic inflammatory process of the kidney, represents an important cause of end stage renal disease that requires long-term hemodialysis (or renal transplantation). U...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000545-40 Sponsor Protocol Number: FELZ01 Start Date*: 2021-08-01
    Sponsor Name:Medical University of Vienna
    Full Title: Safety, Tolerability and Efficacy of Monoclonal CD38 Antibody Felzartamab in Late Antibody-Mediated Renal Allograft Rejection – A Phase 2 Pilot Trial
    Medical condition: Late active or chronic active antibody-mediated rejection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000678-27 Sponsor Protocol Number: CABL001J12301 Start Date*: 2021-08-10
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase III, multi-center, open-label, randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leuk...
    Medical condition: Chronic Myelogenous Leukemia in chronic phase (CML-CP) in newly diagnosed patients
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10009012 Chronic myelogenous leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) HU (Trial now transitioned) DE (Ongoing) CZ (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) SK (Trial now transitioned) SE (Trial now transitioned) AT (Ongoing) NO (Trial now transitioned) BE (Trial now transitioned) BG (Ongoing) FI (Trial now transitioned) NL (Completed) DK (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000424-25 Sponsor Protocol Number: 1508175 Start Date*: 2016-04-12
    Sponsor Name:CHU Saint-Etienne
    Full Title: Low-molecular-weight heparin in constituted vascular intrauterine growth restriction. Randomized multicenter trial
    Medical condition: Intrauterine growth restriction (IUGR)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004868 10022819 Intrauterine growth retardation LLT
    20.0 100000004868 10048489 Intrauterine growth retard LLT
    20.0 100000004868 10048488 Growth intrauterine retard LLT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003398-79 Sponsor Protocol Number: MH21HEM Start Date*: 2023-05-11
    Sponsor Name:Princess Máxima Center for pediatric oncology
    Full Title: International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies in children Subprotocol D: Trametinib + Dexamethasone + C...
    Medical condition: Molecularly profiled r/r ALL/LBL whose tumor harbors an actionable event that can be targeted by the investigational agents. In this subprotocol, patients must present alterations in the RAS signal...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004760-21 Sponsor Protocol Number: BIO-TAILOR Start Date*: 2020-10-07
    Sponsor Name:FONDAZIONE MELANOMA ONLUS
    Full Title: Dabrafenib and trametinib in circulating free DNA BRAFV600 mutated metastatic melanoma patients: a prospective phase II, open label, multicentre study – (Bioliquid TAILOR study – BIO-TAILOR)
    Medical condition: Metastatic melanoma patients with tissue BRAFWT signature and a molecular shift to circulating free DNA BRAF mutated positive melanomas upon progression to an anti PD-1 therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-001594-24 Sponsor Protocol Number: CABL001E2201 Start Date*: 2018-10-17
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase 2, multi-center, open-label, randomized study of oral asciminib added to imatinib versus continued imatinib versus switch to nilotinib in patients with CML-CP who have been previously treat...
    Medical condition: Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with imatinib and have not achieved deep molecular response
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009012 Chronic myelogenous leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) PT (Completed) GB (GB - no longer in EU/EEA) DE (Completed) PL (Completed) DK (Completed) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-001220-30 Sponsor Protocol Number: EGF117165 Start Date*: 2014-07-25
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: An Open-Label, Phase II, Study to Evaluate Biomarkers Associated with Response to Subsequent Therapies in Subjects with HER2-Positive Metastatic Breast Cancer Receiving Treatment with Trastuzumab i...
    Medical condition: HER2 positive Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Prematurely Ended) IT (Completed) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002914-10 Sponsor Protocol Number: 66856 Start Date*: 2019-09-16
    Sponsor Name:Erasmus MC Cancer Institute
    Full Title: FUnctional selection of advanced breast cancer patients for Talazoparib treatment Using the REpair Capacity (RECAP) test: The FUTURE trial
    Medical condition: Advanced or metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002474-30 Sponsor Protocol Number: 2019-002474-30 Start Date*: 2019-12-20
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: PERSONALIZED MOLECULAR DRIVEN SURGERY ACCORDING TO BRCA MUTATIONAL STATUS IN ADVANCED EPITHELIAL OVARIAN CANCER PATIENTS WITH HIGH TUMOR LOAD
    Medical condition: ADVANCED OVARIAN CARCINOMA
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10054913 Serous cystadenocarcinoma ovary PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-003069-39 Sponsor Protocol Number: VARIANT Start Date*: 2023-06-01
    Sponsor Name:Friedrich-Schiller-Universität Jena
    Full Title: Venetoclax after TKI to target persisting stem cells in CML
    Medical condition: Chronic Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10009700 CML LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-002608-16 Sponsor Protocol Number: NVALT-8B Start Date*: 2009-07-13
    Sponsor Name:UMCG
    Full Title: A randomized phase III study of adjuvant chemotherapy with or without low-molecular weight heparin in patients with high risk for recurrence and completely resected non-small-cell lung cancer: NVAL...
    Medical condition: This is a randomized multicenter phase III study. Patient with a high SUVof the primary tumor prior to surgery will be randomised to four cycles of pemetrexed and cisplatin with or without nadropar...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000518-40 Sponsor Protocol Number: RAINBO-MMRd-GREEN-ENGOT-EC14_02 Start Date*: 2022-01-17
    Sponsor Name:Leiden University Medical Center
    Full Title: RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features, TransPORTEC platform trials - The MMRD-GREEN trial -
    Medical condition: Endometrial Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001606-14 Sponsor Protocol Number: 2017/2555 Start Date*: 2017-10-10
    Sponsor Name:Gustave Roussy
    Full Title: A study of patient preference between ODM-201 and Enzalutamide in men with metastatic castrate-resistant prostate cancer
    Medical condition: Metastatic Castration resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001617-12 Sponsor Protocol Number: AP24534-14-203 Start Date*: 2017-10-09
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
    Medical condition: Chronic Phase Chronic Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10054352 Chronic phase chronic myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) DE (Completed) FI (Prematurely Ended) ES (Ongoing) DK (Completed) NO (Ongoing) BE (Completed) FR (Trial now transitioned) NL (Ongoing) PT (Completed) PL (Trial now transitioned) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000397-30 Sponsor Protocol Number: Ponatinib-3001 Start Date*: 2018-10-23
    Sponsor Name:Millenium Pharmaceuticals, Inc (a wholly owned subsidiary of Takeda pharmaceutical Company Limited)
    Full Title: A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelp...
    Medical condition: Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10080018 Philadelphia positive acute lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FI (Completed) BG (Completed) PL (Trial now transitioned) AT (Trial now transitioned) GR (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002525-29 Sponsor Protocol Number: UC-0140/1206 Start Date*: 2013-03-08
    Sponsor Name:UNICANCER
    Full Title: A phase II trial evaluating the Activity of Abiraterone Acetate plus Prednisone in Patients with a Molecular Apocrine HER2-negative locally advanced or metastatic Breast Cancer.
    Medical condition: Molecular apocrine locally advanced or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-001169-18 Sponsor Protocol Number: 2012-001 Start Date*: 2014-07-30
    Sponsor Name:Onyx Therapeutics, Inc.
    Full Title: Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma
    Medical condition: Relapsed and/or Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-002361-17 Sponsor Protocol Number: AML2521 Start Date*: 2021-11-17
    Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS
    Full Title: A multicentric phase 2 study of venetoclax and azacitidine for the management of the molecular relapse/progression in adult NPM1- mutaded acute myeloid leukemia.
    Medical condition: Acute Myeloid Leukemia with NPM1 mutation.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10081513 Acute myeloid leukaemia refractory PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060558 Acute myeloid leukemia recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003248-26 Sponsor Protocol Number: TUD-VINC01-080 Start Date*: 2023-06-01
    Sponsor Name:Technische Universität Dresden
    Full Title: Venetoclax plus Azacitidine versus Standard intensive Chemotherapy for Patients with newly diagnosed Acute Myeloid Leukemia (AML) and NPM1 Mutations eligible for intensive Treatment (VINCENT)
    Medical condition: Patients 18-70 years eligible for intensive therapy with newly diagnosed acute myeloid leukemia (AML) harboring an NPM1 mutation and no activating FLT3 mutation
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA